Literature DB >> 32387659

Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.

Joseph F Merola1, Robert Sidbury2, Andreas Wollenberg3, Zhen Chen4, Annie Zhang5, Brad Shumel4, Ana B Rossi6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32387659     DOI： 10.1016/j.jaad.2020.05.003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  2 in total

1.  Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.

Authors:  Jonathan I Silverberg; Eric L Simpson; Mark Boguniewicz; Marjolein S De Bruin-Weller; Peter Foley; Yoko Kataoka; Gaëlle Bégo-Le-Bagousse; Zhen Chen; Brad Shumel; Jingdong Chao; Ana B Rossi
Journal:  Acta Derm Venereol       Date:  2021-11-10       Impact factor: 3.875

2.  Keratinocyte EGF signalling dominates in atopic dermatitis lesions: A comparative RNAseq analysis.

Authors:  Kate Timms; Hui Guo; Peter Arkwright; Joanne Pennock
Journal:  Exp Dermatol       Date:  2022-05-15       Impact factor: 4.511
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.